[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"normal-pregnancy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:normal-pregnancy":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100612210","comparison-between-using-10min-ctg-in-fetal-monitoring-instead-of-30min-monitoring-in-low-resources-overcrowded-hospitals-100612210",false,"NCT07250620","Comparison Between Using 10min CTG in Fetal Monitoring Instead of 30min Monitoring in Low Resources Overcrowded Hospitals.","Diagnostic Accuracy of 10-Minute Vs 30-Minute CTG in Intrapartum Fetal Monitoring.","Inclusion Criteria:\n\n* Singleton pregnancy.\n* Gestational age ≥ 37 weeks.\n* Vertex presentation.\n* Active first stage of labor (cervical dilation ≥ 4 cm).\n* Low-risk pregnancy (no hypertension, diabetes, IUGR, or other significant complications).\n\nExclusion Criteria:\n\n* • Multiple gestation.\n\n  * Known major fetal anomaly.\n  * Non-vertex presentation.\n  * Indication for continuous CTG (e.g., meconium-stained liquor, antepartum hemorrhage).\n  * Maternal refusal.","FEMALE","18 Years",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","Cardiotocography (CTG) is a cornerstone of intrapartum fetal monitoring but requires a minimum of 30 minutes for a reliable trace, creating a significant bottleneck in high-volume, low-resource settings like Egypt As it is time-consuming and resource intensive. This leads to delays in care and increased workload for healthcare providers. A shortened, yet accurate, CTG protocol could drastically improve workflow and resource allocation without compromising fetal safety.",[24,25],"Normal Pregnancy","Labor Active Dilated Cm",[27,28],"CTG","Fetal monitoring","NOT_YET_RECRUITING","2025-11-23",{"date":32,"type":33},"2025-11-26","ACTUAL",{"date":35,"type":20},"2025-12-17",{"date":37,"type":20},"2026-12",{"name":39,"class":40},"Assiut University","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":51,"conditions":52,"keywords":53,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100393212","using-cotyledon-perfusion-to-study-drugs-transfer-across-the-placenta-100393212","NCT04400084","Using Cotyledon Perfusion to Study Drugs Transfer Across the Placenta","Ex Vivo Study of Drugs Transfer Across the Placenta","DRUGS-PTP","Inclusion Criteria:\n\n* pregnant women older than 18 years,\n* patient with social security or health insurance,\n* from the 24th week of amenorrhea,\n* patient who has given her consent,\n\nExclusion Criteria:\n\n* Maternal pathologies pre-existing pregnancy :\n\n  * diabetes-like vascular disease,\n  * arterial hypertension,\n  * known prothrombotic pathology, history of venous thrombosis or pulmonary embolism,\n  * maternal serology HIV+, BHV+, CHV+ and syphilis,\n* Pregnancy and fetal pathologies :\n\n  * pre-eclampsia,\n  * delayed growth in utero (can affect placental circulation),\n  * gestational diabetes without insulin,\n  * fetal malformation,\n  * known genetic pathology,\n* Patient under tutorship or curatorship, or not speaking french,\n* Patient who has not given her consent",{"count":50,"type":20},2000,"Drug prescriptions are usual during pregnancy however women and their fetuses still remain an orphan population with regard to drugs efficacy and safety clinical studies. Most xenobiotics diffuse through the placenta and some of them can alter fetus development resulting in structural abnormalities, growth or functional deficiencies. The aim of the study is to study the drug transfer using human placenta after delivery.",[24],[54,55,56],"Placenta","Drug","Transplacental transfer","RECRUITING","2025-09-05",{"date":60,"type":33},"2025-09-12",{"date":62,"type":33},"2020-06-05",{"date":64,"type":20},"2030-06",{"name":66,"class":40},"Assistance Publique - Hôpitaux de Paris",1]